Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-tumor medicine composition and purpose thereof

A technology of anti-tumor drugs and compositions, which is applied in the field of anti-tumor drug compositions and pharmaceutical compositions containing arctigenin and nitrosourea alkylating agents, which can solve the problems of large side effects, high treatment costs, and long duration of drug effects and other problems, to achieve the effect of reducing toxic and side effects, obvious synergistic effect, and clear ingredients

Active Publication Date: 2012-03-14
SHANDONG NEWTIME PHARMA
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In order to solve the shortcomings of existing tumor therapeutic drugs in clinical application, especially the defects of large side effects and high treatment cost in most current tumor therapeutic drugs, the present invention provides a drug with long drug effect time, low price and less side effects combination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor medicine composition and purpose thereof
  • Anti-tumor medicine composition and purpose thereof
  • Anti-tumor medicine composition and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Embodiment 1 Preparation of arctigenin and carmustine composition microemulsion preparation

[0061] Table 2 Arctigenin and carmustine composition microemulsion preparation

[0062]

[0063] Preparation process: Weigh 30mg of caprylic acid glyceride and 50mg of emulsifier OP, add it to 20mg of propylene glycol, and mix well to obtain a suspension solution. Accurately weigh 25 mg arctigenin and 2.5 mg carmustine, add them to the suspension solution respectively, and ultrasonically dissolve arctigenin and carmustine to obtain a microemulsion of arctigenin and carmustine composition concentrate. The microemulsion concentrate obtained above is diluted with water according to the weight ratio of 1:10-20 to a clear solution to obtain the microemulsion.

Embodiment 2

[0064] Embodiment 2 Preparation of arctigenin and lomustine composition tablet

[0065] The tablet of table 3 arctigenin and lomustine composition

[0066]

[0067] Preparation process: pass arctigenin and lomustine through 80 mesh sieve respectively, weigh according to the prescription amount, mix evenly, then mix evenly with hydroxypropyl cyclodextrin in equal increments, pass through 60 mesh sieve, and then mix with Mix the rest of the excipients in the prescribed amount evenly, measure the content of the semi-finished product, calculate the weight of the tablet, and press the tablet.

Embodiment 3

[0068] Embodiment 3 Preparation of arctigenin and carmustine composition microemulsion preparation

[0069] Table 4 arctigenin and carmustine composition microemulsion preparation

[0070]

[0071]

[0072] Preparation process: Weigh the prescription amount of medium-chain fatty acid glycerides, polyoxyethylene castor oil EL-40, 1,2-propylene glycol, and absolute ethanol, mix and stir evenly, then add arctigenin and carmustine to dissolve, and also Ultrasonic treatment can be used to speed up the dissolution to obtain a clear concentrated solution, which is the arctigenin microemulsion concentrate. The microemulsion concentrate obtained above is diluted with water according to the weight ratio of 1:10-20 to a clear solution to obtain the microemulsion.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a solid tumor resisting medicine composition with arctigenin and nitrosourea alkylating agent anti-tumor medicines as active components. The weight ratio of arctigenin to nitrosourea alkylating agent anti-tumor medicines is 1:0.001-1000, and preferably 1:0.01-600. The anti-tumor medicine composition provided by the invention is advantaged in clear components, wide anti-tumor spectrum, substantial treatment effect against various tumors, low price, low side-effects, and good clinical application prospect.

Description

technical field [0001] The invention relates to an antineoplastic pharmaceutical composition and its use, in particular to a pharmaceutical composition containing arctigenin and a nitrosourea alkylating agent and its use against solid tumors, belonging to the technical field of medicines. Background technique [0002] Alkylating agents are a class of anti-tumor drugs commonly used in clinical practice, and are chemical substances that can transfer small hydrocarbon groups to other molecules. The common feature of alkylating agents is that they have one or more highly active alkylating groups, which can combine with the protein and nucleic acid of the cell in the body, causing the protein and nucleic acid to lose their normal physiological activity, thereby harming the cell and inhibiting the division of cancer cells . Alkylating agents are non-specific drugs for the cell cycle, and generally have a strong killing effect on cells in the M phase and G1 phase. Small doses can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/365A61P35/02
Inventor 赵志全王洪臣
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com